KINIKSA PHARMACEUTICALS, LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.86 USD | -0.50% |
|
-4.18% | -3.31% |
| Apr. 03 | Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating | MT |
| Apr. 02 | Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart | CI |
Financials (USD)
| Sales 2024 * | 383M | Sales 2025 * | 513M | Capitalization | 1.2B |
|---|---|---|---|---|---|
| Net income 2024 * | -10M | Net income 2025 * | 1M | EV / Sales 2024 * | 2.51 x |
| Net cash position 2024 * | 236M | Net cash position 2025 * | 379M | EV / Sales 2025 * | 1.6 x |
| P/E ratio 2024 * |
-104
x | P/E ratio 2025 * |
347
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals, Ltd.
More recommendations
More press releases
| 1 day | +0.38% | ||
| 1 week | -4.18% | ||
| Current month | -14.04% | ||
| 1 month | -13.38% | ||
| 3 months | -9.59% | ||
| 6 months | +1.86% | ||
| Current year | -3.31% |
1 week
16.80
17.71
1 month
16.8020.32
Current year
16.8022.09
1 year
10.6522.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 15-06-30 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 15-06-30 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-09-30 |
Barry D. Quart
BRD | Director/Board Member | 67 | 15-09-30 |
Thomas Malley
BRD | Director/Board Member | 55 | 16-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 16.94 | -0.03% | 179 593 |
| 24-04-17 | 16.95 | -2.92% | 389,307 |
| 24-04-16 | 17.46 | +0.11% | 304,967 |
| 24-04-15 | 17.44 | +0.87% | 314,106 |
| 24-04-12 | 17.29 | -2.32% | 257,002 |
Delayed Quote Nasdaq, April 18, 2024 at 01:51 pm EDT
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.95
USD
Average target price
28.2
USD
Spread / Average Target
+66.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.31% | 1.2B | |
| -3.35% | 102B | |
| +2.22% | 96.84B | |
| -0.44% | 21.48B | |
| -18.50% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.32% | 13.78B | |
| +0.64% | 13.4B | |
| +21.02% | 11.06B |
- Stock Market
- Equities
- KNSA Stock
